Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
Join this webinar to hear about the latest RMM technology and how it aligns with UPS testing criteria.
news

DRC announces plans to use second Ebola vaccine

Health authorities in the Democratic Republic of Congo are planning to use a second vaccine to treat the Ebola virus.

The Democratic Republic of Congo (DRC) has announced plans to utilise a second Ebola vaccine to combat the outbreak of the condition, reports the World Health Organization (WHO).

The medication, manufactured by Johnson & Johnson (J&J), will be introduced from mid-October. It is delivered in two-doses, 56 days apart. The vaccine would complement the rVSV-ZEBOV-GP Merck vaccine currently in use.

Previously, health authorities in DRC had rejected the use of the J&J vaccine, which is being trialled in Uganda and Guinea.

DRC rejects clinical trial for experimental Ebola vaccine

In a statement reported by Reuters, the Ebola response team said: “It is a vaccine that other countries already use. Why can’t we use it in Congo to protect our population?”

“The DRC authorities, in deciding to deploy the second experimental vaccine to extend protection against this deadly virus, have once again shown leadership and their determination to end this outbreak as soon as possible,” said WHO Director-General, Dr Tedros Adhanom Ghebreyesus.